Haedersdal C, Mehlsen J, Stenver D, Nielsen B, Jeppesen L, Winther K
Department of Clinical Physiology, Hvidovre and Frederiksberg Hospital, Denmark.
Angiology. 1994 Mar;45(3):231-4. doi: 10.1177/000331979404500309.
The anemia in patients with chronic renal failure can be corrected through treatment with recombinant human erythropoietin treatment. This correction is associated with changes in the rheologic variables, which could explain the changes in hemodynamics found by many investigators. The authors have followed up 11 patients with chronic renal failure on hemodialysis before and during six months of therapy with erythropoietin. The measurements were made before treatment, after four months of therapy, and after six months of therapy. The measurements included hematocrit, osmotic resistance of the red blood cells, red blood cell volume, plasma volume, heart rate, arterial blood pressure, and cardiac output measured by the indicator dilution method. They found a significant increase in hematocrit hemoglobin, and red blood cell volume and a decrease in osmotic resistance while the hemodynamic variables were unchanged. The conclude that, in spite of changes in rheologic variables, increasing viscosity of the blood and thus possibly increasing the peripheral resistance, these had no effect on the cardiovascular state. Erythropoietin treatment improves the subjective well-being in patients on chronic hemodialysis without compromising their cardiovascular function.
慢性肾衰竭患者的贫血可通过重组人促红细胞生成素治疗得到纠正。这种纠正与血液流变学变量的变化有关，这可以解释许多研究者所发现的血液动力学变化。作者对11例接受血液透析的慢性肾衰竭患者在促红细胞生成素治疗前及治疗6个月期间进行了随访。测量在治疗前、治疗4个月后和治疗6个月后进行。测量指标包括血细胞比容、红细胞渗透阻力、红细胞体积、血浆体积、心率、动脉血压以及通过指示剂稀释法测量的心输出量。他们发现血细胞比容、血红蛋白和红细胞体积显著增加，渗透阻力降低，而血液动力学变量未发生变化。他们得出结论，尽管血液流变学变量发生了变化，血液粘度增加，从而可能增加外周阻力，但这些对心血管状态没有影响。促红细胞生成素治疗可改善慢性血液透析患者的主观幸福感，而不会损害其心血管功能。
